Multiomic Health
  • home.
  • about.
  • focus.
  • approach.
  • news.
  • team.
  • investors.
  • contact.
1 July 2022 by Multiomic

The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?

The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?
1 July 2022 by Multiomic

Click here to listen to the podcast on the Pharma Letter website.

The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?

July 01, 2022 With Robert Thong, chief executive of MultiOmic Health

Interest in the potential for artificial intelligence to transform different aspects of the drug discovery and development process is at an all-time high.

According to industry analyst GlobalData, the number of AI deals in pharma has doubled in the last three years, reaching 85 in 2021, and more pharmaceutical companies are hiring for AI roles than ever before.

Another way of gauging interest is to look at the number of AI-based patents granted over time, with analysts recording a three-fold increase since 2015.

While the broad picture is clear, a detailed look at where this activity is focused reveals that not all therapy areas have received the same level of attention, with oncology attracting much of the interest.

One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsewhere.

MultiOmic Health is targeting a huge area of unmet medical need and a panoply of conditions including diabetes, heart disease, liver disease and kidney disease.

Together, such metabolic disorders account for the largest proportion of the world’s healthcare spend, nearly $2 trillion, with that amount set to rise as global populations age.

In this week’s episode of The Pharma Letter Podcast, MultiOmic chief executive Robert Thong discusses his firm’s progress and ambitions for the future.

Previous articleMultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic DiseaseNext article Understanding the AI-enabled Drug Discovery Landscape

About Multiomic

Multiomic is a next-generation precision medicine business, applying computational systems biology to develop and commercialize data assets for metabolic syndrome — the world’s largest healthcare burden.

With our unique combination of data science and biology expertise, we are enabling data-driven development of therapeutics and are bringing understanding into complex biological systems.

Recent Posts

Understanding the AI-enabled Drug Discovery Landscape8 July 2022
The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?1 July 2022
MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease30 June 2022

Categories

  • Articles
  • Blog Post
  • Interview
  • Podcast
  • Press Release

Tags

AI Drug Discovery Feature Mesh Bio MOHSAIC Multiomic Health Nature Omics Partnership Podcast Precision Medicine Press Release Robert Thong The Pharma Letter

About

Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop  and commercialize data assets for metabolic syndrome

Contact

info@multiomic.healthhttps://multiomic.health/
Multiomic Health Limited. All Rights Reserved.

© Multiomic Health Limited 2021. All Rights Reserved.

Multiomic Health Limited is a Registered UK Company

Company Number: 13246608

Company Address: Epworth House, 25 City Road, Shoreditch, London, EC1Y 1AA

CONTACT

info@multiomic.health

COPYRIGHT notice

All the content on multiomic.health is either self-generated by Multiomic Health Limited, or readily available in various places on the Internet and therefore believed to be in the public domain. Transparent PNG images uploaded are believed to be posted within our rights according to the U.S. Copyright Fair Use Act (Title 17, U.S. Code.) and comparable regulations in other countries.

multiomic.health complies with 17 U.S.C. 512 and the Digital Millennium Copyright Act (“DMCA”). It is our policy to respond to any infringement notices and take appropriate actions under the DMCA and other applicable intellectual property laws.

If by any chance your copyrighted material has been posted on multiomic.health or if links to your copyrighted material are returned through a search engine and you wish this material removed, please provide a written statement identifying in sufficient detail the copyrighted work claimed to have been infringed. You may use the contact form at the end of the landing page for the purposes of such written communication.

 

DATA SOURCES

https://ourworldindata.org/causes-of-death

https://ourworldindata.org/obesity

https://bmjopen.bmj.com/content/10/8/e036663

How Prevalent is NASH?

https://www.heart.org/-/media/phd-files-2/science-news/2/2021-heart-and-stroke-stat-update/2021_heart_disease_and_stroke_statistics_update_fact_sheet_at_a_glance.pdf?la=en

https://www.ahajournals.org/doi/10.1161/CIR.0000000000000757

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278808/

https://www.cdc.gov/obesity/data/adult.html

https://stop.publichealth.gwu.edu/sites/stop.publichealth.gwu.edu/files/documents/Fast%20Facts%20Cost%20of%20Obesity.pdf

https://www.sciencedirect.com/science/article/abs/pii/S2211883717300187

https://journals.lww.com/jcge/Abstract/2015/09000/The_Epidemiology_of_Cirrhosis_in_the_United.12.aspx#:~:text=The%20prevalence%20of%20cirrhosis%20in%20the%20United%20States%20was%20approximately,unaware%20of%20having%20liver%20disease

How Prevalent is NASH?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743497/#:~:text=In%20the%20United%20States%2C%20NAFLD,nearly%2025%25%20progress%20to%20NASH

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767767/

https://www.nature.com/articles/nrgastro.2017.109

https://www.diabetes.org/resources/statistics/statistics-about-diabetes#:~:text=Prevalence%3A%20In%202018%2C%2034.2%20million,of%20the%20population%2C%20had%20diabetes.&text=Undiagnosed%3A%20Of%20the%2034.2%20million,and%207.3%20million%20were%20undiagnos

https://www.kcl.ac.uk/news/spotlight/global-cost-of-diabetes-set-to-double-by-2030

https://www.kcl.ac.uk/news/spotlight/global-cost-of-diabetes-set-to-double-by-2030

https://www.worldobesity.org/news/world-obesity-day-all-countries-significantly-off-track-to-meet-2025-who-targets-on-obesity